Portage biotech presents updates on its inkt and adenosine programs at the society for immunotherapy of cancer's (sitc) 38th annual meeting

Westport, conn., nov. 06, 2023 (globe newswire) -- portage biotech inc. (nasdaq: prtg), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced the presentations of updates from its ongoing import-201 phase 1/2 trial of port-2 (imm60), an invariant natural killer t cell (inkt) engager for patients with nsclc and advanced melanoma, and its adport-601 adaptive phase 1a/1b trial for port-6 (a2a inhibitor) and port-7 (a2b inhibitor) in multiple solid tumors at sitc.
ATON Ratings Summary
ATON Quant Ranking